CP109

CP109 is a preclinical-stage long-acting injectable (LAI) combination therapy being developed by Consegna Pharma for the treatment of tuberculosis. The formulation is designed to provide a sustained release of anti-mycobacterial small molecules over a 60-day duration following a single administration. This approach is intended to improve patient compliance and treatment outcomes by reducing the pill burden and frequency of dosing associated with standard tuberculosis therapy. The specific active pharmaceutical ingredients within the combination have not been publicly identified, but the program leverages Consegna's proprietary delivery technology to achieve a long-acting pharmacokinetic profile.

Other names

Anti-Tuberculosis ComboAnti-Tuberculosis Combo 60-dayAnti-tuberculosis combination